Common fragile sites (CFSs) are large genomic regions present in all individuals that are highly unstable and prone to breakage and rearrangement, especially in cancer cells with genomic instability. Eight of the 90 known CFSs have been precisely defined and five of these span genes that extend from 700 kb to over 1.5 Mb of genomic sequence. Although these genes reside within some of the most unstable chromosomal regions in the human genome, they are highly conserved evolutionarily. These genes are targets for large chromosomal deletions and rearrangements in cancer and are frequently inactivated in multiple tumor types. There is also an association between these genes and cellular responses to stress. Based upon the association between large genes and CFSs, we began to systematically test other large genes derived from chromosomal regions that were known to contain a CFS. In this study, we demonstrate that the 730 kb retinoic acid receptor-related orphan receptor alpha (RORA) gene is derived from the middle of the FRA15A (15q22.2) CFS. Although this gene is expressed in normal breast, prostate and ovarian epithelium, it is frequently inactivated in cancers that arise from these organs. RORA was previously shown to be involved in the cellular response to hypoxia and here we demonstrate changes in the amount of RORA message produced in cells exposed to a variety of different cellular stresses. Our results demonstrate that RORA is another very large CFS gene that is inactivated in multiple tumors. In addition, RORA appears to play a critical role in responses to cellular stress, lending further support to the idea that the large CFS genes function as part of a highly conserved stress response network that is uniquely susceptible to genomic instability in cancer cells.
Introduction
Fragile sites, which consist of rare fragile sites (RFSs) and common fragile sites (CFSs), are specific chromosomal loci that non-randomly exhibit gaps or breaks in response to specific culture conditions or exposure to certain chemical agents. In contrast to the RFSs, which are found in less than 5% of the population and whose instability is associated with expansion of some repeat sequence, the CFSs are present in all individuals and are not found to be associated with any simple unstable repeat sequences (Sutherland and Richards, 1995) .
So far, a total of 90 CFS regions have been identified throughout the human genome (Buttel et al., 2004) . CFSs are highly unstable and recombinogenic regions of the genome. They are preferential sites of sister chromatid exchange, translocations, deletions, intrachromosomal gene amplification and integration of DNA from tumor-associated viruses. As the CFS regions are so unstable, it has been presumed that genes residing within these regions are frequently altered by the deletions and rearrangements that occur in genetically unstable cancer cells. Therefore, it has been proposed that CFSs, and the genes located within them, play a mechanistic role in the initiation or progression of human cancers (Arlt et al., 2003; Buttel et al., 2004) .
At this point only a few of the CFSs have been fully characterized. The most unstable regions include FRA3B (3p14.2) and FRA16D (16q23.2) (Smith et al., 1998; Sutherland et al., 1998) . These CFSs are large regions of genomic instability spanning multiple megabases. Contained within the most unstable regions within these CFSs are genes that themselves span very large genomic regions. For example, the total size of the most unstable CFS (FRA3B) is over 4 Mb and spanning the most unstable portion of this CFS is the extremely large FHIT gene (Huebner et al., 1997; Becker et al., 2002) . The genomic size of FHIT is over 1.5 Mb, but it is comprised of only nine small exons that make a 1095 bp final transcript. Surprisingly, FHIT is not a traditional mutational target in human cancer as only a single gastric tumor has been identified with a point mutation in this gene (Gemma et al., 1997) . However, there are frequent deletions and other alterations within this large gene in many different types of cancer . In addition, many primary tumors do not express the Fhit protein (Becker-Andre et al., 1993; Becker et al., 2002) . WWOX, which spans 1.0 Mb of genomic sequence in 16q23.2, has been identified within FRA16D, another chromosomal region frequently deleted in multiple cancers (Ludes-Meyers et al., 2003) . WWOX, like FHIT, is not a traditional mutational target in cancer, but there are deletions and other alterations within the highly unstable region surrounding WWOX, and it is also frequently inactivated in many different tumors (Finnis et al., 2005) . In response to specific types of stress, WWOX is specifically phosphorylated, and phosphorylated WWOX then binds to p53, translocates to the nucleus and induces apoptosis (Chang et al., 2003) . Functional studies have demonstrated that both FHIT and WWOX may work as tumor suppressors (Bednarek et al., 2001; Dumon et al., 2001) .
These large CFS genes are remarkably evolutionarily conserved not only in the small exons but also in the large intronic regions. In addition, the chromosomal regions spanning these large genes in the mouse are also CFSs (Krummel et al., 2002; Matsuyama et al., 2003) ; thus, the large genes and highly unstable regions are co-conserved, suggesting that together they serve some important cellular function. As the CFS regions and the large size CFS genes were associated with human cancer development, we began to systematically test a number of large genes that were derived from chromosomal regions known to contain a CFS. It was found that the retinoid-related orphan receptor alpha (RORA) gene, which encodes an ROR and is 730 kb size, is located in the middle of the FRA15A (15q22.2) CFS.
RORA encodes an ROR, which functions as an evolutionarily related transcription factor and belongs to the steroid hormone receptor superfamily (Jetten, 2004) . It consists of three members: RORA (also named NRF1 by the Nuclear Receptor Nomenclature Committee), RORB (NRF2) (Carlberg et al., 1994) and RORC (NRF3, or TOR) (Hirose et al., 1994) . It has been demonstrated that these receptors are critical in the regulation of a number of physiological processes. However, the involvement of individual RORs in possible physiological function in vivo is still poorly understood. The RORA gene produces four isoforms (RORA1-RORA4), which only differ in their Nterminal regions and demonstrate distinct DNA-binding and transactivation properties (Becker-Andre et al., 1993; Giguere et al., 1994; Matysiak-Scholze and Nehls, 1997) . In the RORA-mutated mouse, staggerer, there are specific cerebellar abnormalities, showing that this nuclear receptor plays a critical role in the development of the cerebellum (Hamilton et al., 1996) . RORA has also been suggested to be involved in lipid metabolism, to possess immunomodulatory activity and to mediate the antiarthritic properties of a class of thiazolidinediones (Missbach et al., 1996) . ROREs (ROR response elements), to which RORA protein binds, have been identified in the promoter region of cell cycle-related genes, such as those of the cyclin-dependent kinase (CDK) inhibitor p21 WAF1/CIP1 (Schrader et al., 1996) , and of cyclin A, as well as in the promoter of N-myc (Lee et al., 1984; Nau et al., 1986) , a gene whose amplification appears to be related to the development of several tumors. It has been reported that ligand-induced activation of RORA significantly reduces the growth of the murine colon 38 adenocarcinoma (Pawlikowski et al., 1999) . Taken together, these observations suggest that unlike the other two members in this family, RORA might be involved in the regulation of cell growth and tumorigenesis.
The goal of this study was to determine if RORA was another large CFS gene and if it was frequently inactivated in multiple tumor types. In addition, we wanted to determine if RORA could also be functioning as a stress-response gene similar to other large CFS genes. We found that RORA is expressed in different human tissues and only two out of its four isoforms are actually transcribed. Then, we showed that the level of RORA is downregulated in breast, ovarian and prostate cancer samples, including primary tumor and cancer cell lines. We also demonstrated that the expression of RORA can be activated by different types of stress treatment. Our data from this study suggested that RORA, another large gene located in a CFS region, plays a role in cellular stress response and is involved in human tumorigenesis.
Results
RORA is derived from the middle of the FRA15A (15q22.2) CFS RORA is derived from human chromosomal band 15q22.2, which also contains the FRA15A CFS. In order to determine if RORA is located within the FRA15A CFS region, we selected a BAC clone (CTD-2034M3) that spans the approximate center of RORA. This BAC was labeled with biotin, and hybridized to metaphase preparations produced from lymphocytes cultured in the presence of 0.4 mM APC for 24 h. In 20 clear metaphases (out of over 700 analysed) with good discernible breakage/decondensation within FRA15A, BAC CTD-2034M3 was found to localize proximal to the region of B/D in 12 metaphases and distal to B/D in another 8. Figure 1 show representative hybridizations demonstrating that RORA lies within the FRA15A region. Based upon the number of times that this BAC hybridized proximal as compared to distal to the region of B/D, we can determine that the center of the RORA gene lies close to the center of the FRA15A CFS. We also determined that the FRA15A CFS has a relatively low level of expression as we had to analyze over 700 metaphases in order to find sufficient cells with B/D at 15q22.2.
RORA and its specific isoforms are expressed in human normal tissues We first investigated whether RORA was expressed in normal human tissues, including the brain, breast, liver, ovary and prostate, and if so, which of the four RORA isoforms was present. Using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and the universal primers for the RORA gene, which amplify one 250 bp fragment located from þ 750 to þ 1005 of the RORA transcript, it was shown that the human RORA gene was transcribed in all these tissue samples ( Figure 2 ). Using specific primers for each of the four different RORA isoforms, we demonstrated that only RORA1 and RORA4 were transcriptionally expressed in normal tissues (Figure 2 ). On the other hand, the level of RORA2 and RORA3 was undetectable, even if the amount of cDNA template or the number of PCR cycles was increased. The same expression pattern of RORA was also found in the normal breast epithelial cell line MCF12F (data not shown). These results suggest that RORA is expressed in normal human tissues and RORA1 and RORA4 are the main transcripts of the RORA gene. These are consistent with the results obtained from other research groups (Lau et al., 1999; Chauvet et al., 2002; Migita et al., 2004) .
RORA is downregulated in cancer, including the breast, ovary and prostate cancer samples In order to understand the role of RORA in the process of human tumorigenesis, the expression level of RORA was measured in several different types of human cancer samples, either in primary tumors or in tumor-derived cell lines. Total RNA was isolated from breast, ovary and prostate samples. cDNA was prepared and the transcriptional level of RORA was examined with semiquantitative RT-PCR using universal RORA primers designed to be able to amplify all four RORA transcripts, if there is any. The results showed that in most cancer samples, the transcriptional level of RORA was significantly decreased compared to that in normal control samples (Figure 3a -c). To confirm that the downregulation of RORA is specific and not because of the bystander effect of an unstable genomic structure, the expression of another two genes, FOXB1 and NARG2, which are located in the same fragile site as RORA, was examined in these cancer samples. It was demonstrated that, in these cancer-derived samples, the transcriptional level of FOXB1 and NARG2 was not affected compared to the level in controls ( Figure 3d ).
The expression of RORA is activated by aphidicolin treatment As the human RORA gene is located in the middle of the CFS FRA15A, it would be interesting to know if the expression status of RORA is affected when the FRA15A CFS was induced. It was well known that the expression of CFS can be induced by aphidicolin (APC), an inhibitor of DNA polymerase alpha and delta (Glover et al., 1984) . The transcriptional level of RORA was checked in the normal breast epithelial cell MCF12F treated with 0.2, 0.4 and 0.8 mM APC for 24 h. A step-wise increase in RORA mRNA was observed with the highest level of RORA expression achieved at 0.8 mM APC treatment (Figure 4 ). On the other hand, the transcriptional level of FOXB1, which is adjacent to RORA on Chromosome 15, was stable under these APC stress conditions (Figure 4) . Meanwhile, the abundance of actin mRNA was also not significantly affected. These results suggest that RORA is specifically upregulated when the expression of CFS increases.
RORA also responds to other types of stress In order to determine whether the activation effect of cellular stresses on RORA gene expression is a general phenomenon, the effect of different types of stresses, including UV, H 2 O 2 and methyl methanesulfonate (MMS), on the amount of RORA transcript and protein in MCF12F cells was observed. Three different dosages of each stress agent were used, specifically 10, 20 and 50 J/M 2 for UV; 100, 200 and 500 mM for H 2 O 2 ; and 0.001, 0.005 and 0.01% for MMS. MCF12F cells were treated with each stress condition for 24 h before cellular total RNA and protein were collected. Using semiquantitative RT-PCR and Western blotting assay, it was shown that there were significant increases of RORA transcript and protein under the stress conditions compared to untreated cells. The results from either semiquantitative RT-PCR or Western blotting assay were consistent. Meanwhile, the expression level of both FOXB1 and NARG2 genes was not affected by any of these stress conditions (data not shown). This effect was specific, since the level of actin transcript and protein was not affected by the treatments (Figure 5 ).
Overexpression of RORA inhibits cellular growth
In order to elucidate the biological function of RORA in the development of human cancers, the RORA gene was re-introduced into MCF12F cells, and its effect on cell proliferation was observed. As shown in Figure 6 , MCF12F cells were transfected with pcDNA3-RORA4, as RORA4 is one of the predominant isoforms of RORA expressed (Chauvet et al., 2002) and RORA1 is more specifically produced in the central nervous system (Matysiak-Scholze and Nehls, 1997). The cell number Figure 6 ). This suggested that increase of RORA expression affected the cell proliferation.
Discussion
CFSs are highly unstable genomic regions that are apparently present in all individuals. While they are characterized utilizing an in vitro assay of chromosomal decondensation/breakage induced by inhibitors of DNA replication, their apparent in vivo significance is that they predispose chromosomes to breakage and rearrangement, especially in developing cancer cells (Huebner et al., 1998; Smith et al., 1998) . The four most active of the CFS regions are FRA3B (3p14.2), FRA16D (16q23.2), FRAXB (Xp22.31) and FRA6E (6q26). Three of these regions, FRA3B, FRA16D and FRA6E, are consistently deleted during the development of many different cancers. Spanning the most unstable regions within each of these three CFS regions are genes that themselves span very large genomic regions, FHIT, WWOX and Parkin, respectively. There are frequent deletions and other alterations in each of these genes in multiple cancers and the proteins encoded by these genes are frequently not expressed in these same cancers (Buttel et al., 2004) . However, these genes are not traditional mutational targets in cancer as there are very few cancers that have point mutations in these genes. This may be because their chromosomal locations within the highly unstable CFSs make larger deletions and other alterations predominant. Although FHIT is not a traditional tumor suppressor gene, it has been demonstrated that the inactivation of this gene results in cells being much more tumor prone, and this can be reversed by putting FHIT back into FHITÀ/À cells (Gopalakrishnan et al., 2003) . The re-introduction of WWOX and Parkin into cell lines that do not express them can sometimes inhibit the growth of these cells as well as result in greater sensitivity to apoptotic induction (Bednarek et al., 2001; Jiang et al., 2004; Wang et al., 2004) . As several of the CFS regions are associated with extremely large genes, we have begun to systematically examine other large genes that are derived from regions known to contain a CFS to determine if they are also CFS genes. This strategy enabled us to identify the 730 kb RORA gene as another gene that spans a CFS region. The RORA gene contains 11 exons that together make a 1.5 kb final processed transcript (Jetten and Ueda, 2002) . The cytogenetic results from this study demonstrate that RORA is derived from the approximate middle of the FRA15A (15q22.2) CFS. In contrast to FRA3B, FRA16D and FRA6E, which are highly active frequently expressed CFSs, FRA15A is expressed at very low frequencies. We therefore did not characterize the entire FRA15A region, but have merely delineated the position of the center of this CFS region.
We have shown that RORA is universally expressed in various normal tissues, including the brain, breast, liver, ovary and prostate. Human RORA produces four isoforms that are identical, except for their aminoterminus (Giguere et al., 1994; Hamilton et al., 1996) . These isoforms are generated by a combination of alternative promoter usage and exon splicing. The RORA1 isoform was reported to be specifically produced in the central nervous system (Matysiak-Scholze and Nehls, 1997), but in this study, we found that both RORA1 and RORA4 were present in an organ other than the brain. This is consistent with the results reported previously. The presence of both RORA1 and RORA4 in various organs suggested that they might be critical in the regulation of certain physiological processes by controlling the expression of their target genes.
It has been reported that RORA appears to be crucial for many cellular physiological processes that occur in tissues such as the cerebellum, adipose, muscle and bone (Jetten, 2004) . However, the precise role that RORA plays in vivo remains to be elucidated, and as a member of the nuclear receptor family, its cognate ligand remains to be identified (Giguere, 1999 ). In the current study, we found that the transcriptional level of RORA was decreased in several different types of cancer, including cancer-derived cell lines and primary tumors. We have now demonstrated that the expression of RORA was activated when the cells were exposed to various types of stress, including UV, MMS and H 2 O 2 . This suggests that RORA could contribute to the development of cancer, and owing to its inactivation, the normal stress response system that RORA is a part of is no longer functional.
The altered level of RORA might affect the expression of its downstream target genes that are normally used to execute its biological function(s). It was previously demonstrated that RORA binds as a monomer or homodimer to regulatory ROREs in the promoter region of its target genes, which include one core motif AGGTCA or two direct AGGTCA repeats spaced by two nucleotides preceded by a six nucleotide long AT-rich sequence (Giguere et al., 1994) . Several genes have been identified as potential target genes of RORA including the CDK inhibitor p21 and N-myc (Dussault and Giguere, 1997) , which are closely related to human cancer development. In this study, a significantly inhibited cell growth was observed when the RORA gene was re-introduced into MCF12F cells. It is suggested that the level of RORA expression does affect cell proliferation. Further experiments are required to understand how RORA itself (and its downstream target genes) is involved in the regulation of cell growth. It has been suggested that RORA significantly decreases cell proliferation and affects cell cycle progression through the modulation of cell cycle-related genes in DU145 androgen-independent prostate cancer cells (Moretti et al., 2001) .
In a previous study, it was demonstrated that hypoxia increased the amount of RORA transcripts (Chauvet et al., 2004) . As hypoxia is an important component of many physiological and pathological processes, this suggests that RORA may be involved in the cellular stress response network. It has been well documented that the response to multiple types of genetic damage is mediated by the DNA damage checkpoint pathway (Nyberg et al., 2002; Laiho and Latonen, 2003) . Recently, another study showed that the components of the DNA damage checkpoint pathway controlled the expression of two CFS genes FHIT and WWOX in response to UV treatment (Ishii et al., 2005) . It was also reported that the expression of CFSs themselves was affected by the S phase and G2/M cellular DNA damage checkpoint protein ATR (ataxia-telangiectasia and Rad3-related; Casper et al., 2002) . This mechanism can be activated when cells are treated with UV or DNA replication blocking agents, such as APC. The deficiency of ATR, but not ATM (ataxia-telangiectasia mutated), caused a significant increase of chromosomal instability after APC treatment. Both the altered expression of CFS genes and increased fragility would result in increased susceptibility to cancer. Further experiments will need to be performed in order to define the connection between RORA and certain checkpoint component(s) and between RORA and its downstream target genes.
RORA mRNA is widely expressed. This contrasts with the more selective expression of RORB and RORC, two other members of the same family (Jetten, 2004) . It was reported that RORB is expressed specifically in the brain (Carlberg et al., 1994) , and RORC is found at high levels in the skeletal muscle (Hirose et al., 1994) . However, we do not have any evidence to rule out the possibility that RORB and RORC also play some role in tumorigenesis in vivo. Actually, it was shown that exogenous expression of either of the two isforms of RORC in T-cell hybridomas inhibited interleukin-2 and Fas ligand expression and blocked T-cell receptor-induced cell proliferation and apoptosis (He et al., 1998; Littman et al., 1999) . Recently, it was reported that RORC is a common integration site in type B leukemogenic virus-induced T-cell lymphomas (Broussard et al., 2004) .
In summary, we have now shown that the very large RORA gene is actually derived from within the most active portion of the FRA15A CFS and that this gene is frequently inactivated in cancers that arise from different types of human tissues. RORA was previously shown to be involved in cellular response to hypoxia, and here we demonstrated changes in the amount of RORA gene product in cells exposed to a variety of different cellular stresses, including UV, MMS and H 2 O 2 . Thus, RORA is another very large CFS gene that is inactivated in multiple tumors. In addition, RORA appears to play a critical role in responses to cellular stress, lending further support to the idea that the large CFS genes function as part of a highly conserved stress response network that is uniquely susceptible to genomic instability in cancer cells.
Materials and methods

Clone selection
A bacterial artificial chromosome (BAC) clone was selected based on its localization within the RORA gene according to the UCSC Human Genome Database. The selected clone for RORA (CTD-2034M3) spans the approximate center of the gene. BAC clone CTD-2034M3 was obtained from Invitrogen and grown according to published procedures. The BAC clone was verified by PCR with primers derived from markers that were spanned by the BAC clone. DNA was then isolated from individual colonies that amplified the correct sized fragment using PCR as described previously.
Cell culture and transfection
The normal breast epithelium cell line MCF12F was obtained from American Type Culture Collection (Rockville, MD, USA). MCF12F cells were routinely grown in DMEM/Ham's F12 supplemented with 20 ng/ml epidermal growth factor (EGF), 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone and 5% horse serum. All the other cell lines were maintained in DMEM medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 100 U/ml penicillin, 100 mg/ml streptomycin at 371C in a humidified atmosphere of 5% CO 2 . Metaphase cell preparations were prepared from mitogen-stimulated peripheral blood cultures obtained from normal individuals. Cultures were established with 9.5 ml RPMI 1640, 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.5 ml lymphocyte-rich blood, and 10 mg/ml PHA (Irvine Scientific, Santa Ana, CA, USA) and incubated at 371C in 5% CO 2 for 72 h. Twenty-four hours prior to harvest, select cultures were inoculated with 0.4 mM APC (Sigma, St Louis, MO, USA). Cell harvest and slide preparation followed routine cytogenetic techniques. The transient transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The construct pcDNA3-RORA4, which overexpresses the product of RORA4, was generously provided by Dr V Giguere at McGill University Health Center.
Cellular stress treatment
For APC and MMS (Sigma, St Louis, MO, USA) treatment, 2 Â 10 5 MCF12F cells were plated in a 60 mm Petri dish and incubated at 371C for overnight. Next day, the fresh medium was exchanged and the chemical was directly added into the medium with different concentrations. Cells were harvested after 24 h incubation and total RNA/protein was prepared. For UV treatment, 2 Â 10 5 MCF12F cells were plated in a 60 mm Petri dish. After overnight incubation at 371C, the medium was extracted and the cells were exposed to 254 nm UV light at different intensities in a UV crosslinker (Fisher model FB-UVXL-1000 at B2400 mW/cm 2 ). Fresh medium was added and cells were incubated for another 24 h before the RNA or protein extraction.
Fluorescence in situ hybridization Fluorescence in situ hybridization (FISH) can be preformed to detect the expression of CFS. RORA spans B730 kb within chromosomal band 15q22.2. A single BAC clone from within the approximate center of this gene was selected to test whether this gene was derived from within the CFS that has been localized to the same chromosomal band. Purified BAC DNA was biotin labeled using a BioNick translation kit (Invitrogen) according to the manufacturer's protocols. The probe was precipitated and hybridized to APC-treated metaphase chromosomes. After overnight hybridization at 371C, slides were washed twice in 2 Â SSC (pH 7.0), twice in 50% 2 Â SSC/50% formamide and twice in 2 Â SSC (pH 7.0). All solutions were at 401C and each wash was 5 min. Slides were then incubated at room temperature in 75 ml of 5% bovine serum albumin/4 Â SSC þ 0.2% Tween-20 solution for 5 min. The detection of the probe signal was performed by applying 75 ml of an avidin/5% bovine serum albumin mixture to each slide, incubating at 371C for 15 min and washing in four changes of 4 Â SSC þ 0.2% Tween-20 solution at 401C for 3 min each. Signals were amplified by applying 75 ml of 5% normal goat serum/4 Â SSC þ 0.2% Tween-20 solution to each slide and incubating for 5 min at room temperature. An anti-avidin/5% normal goat serum solution (75 ml) was then applied to each slide and then incubated at 371C for 15 min, and washed in four changes of 4 Â SSC þ 0.2% Tween-20 solution at 401C for 3 min each. Chromosomes were counterstained with DAPI (Vector Laboratories, Burlingame, CA, USA). Photomicroscopy was performed using a Zeiss Axioplan flurorescence microscope equipped with MacProbe software (Applied Imaging, San Jose, CA, USA).
Semiquantitative RT-PCR Total RNA was isolated from cell lines and primary tumor samples with a Versagenet RNA Purification Kit (Gentra, Minneapolis, MN, USA) according to the manufacturer's protocol. Reverse transcription was performed at 501C for 1 h in a total volume of 20 ml using a ThemoScriptt RT-PCR Kit (Invitrogen) according to the manufacturer's protocol. The RORA isoform-specific PCR primer sequences were deduced from the published sequences of the human and mouse RORA1 and RORA4, and the human RORA2 and RORA3 cDNA (Genebank Accession numbers U04897, U53228, L14611, Y08640, U04898 and U04899). The universal primers used for all RORA transcripts are RORA-5 0 , 5 0 -GTCACG CAGCTTCTACCTGGAC-3 0 and RORA-3 0 , 5 0 -GTGTTGTT CTGAGAGTGAAAGGCAGG-3 0 . Each of the RORA1-4 transcripts was analysed using the RORA-3 0 isoprimer, 5 0 -AACAGTTCTTCTGACGAGGACAGG-3 0 for all the isoforms, and the RORA1-5 0 , 5 0 -GAGGTATCTCAGTCACGA AC-3 0 (183 bp product) for RORA1; the RORA2-5 0 primer, 5 0 -CAGTGTATCCTGTCTTCAGG-3 0 (274 bp product) for RORA2; the RORA3-5 0 primer, 5 0 -ACATAAACTGGGATG GAGCC-3 0 (234 bp product) for RORA3; and the RORA4-5 0 primer, 5 0 -TGTGATCGCAGCGATGAAAG-3 0 (170 bp product) for RORA4. The primers for FOXB1 are 5 0 -CCGCCC TACTCGTACATCTC-3 0 and 5 0 -CGGGATCTTGATGAAG CAGT-3 0 . The primers for NARG2 are 5 0 -CCCTTGAAGTT TGAGGAGGA-3 0 and 5 0 -GTCGCAACAGACTGGCAA TA-3 0 . The amount of actin transcripts was used as the loading control, which was detected with the control primers actin-5 0 , 5 0 -ATGAGGTAGTCAGTCAGGTC-3 0 ; and actin-3 0 , 5 0 -GCTCCGGCATGTGCAAGG-3 0 . The thermal cycle conditions included one cycle at 951C for 10 min, 30 cycle of (951C for 30 s, 551C for 30 s, 721C for 30 s) and one cycle at 721C for 10 min.
Western blotting assay Cultured cells were harvested and incubated in lysis buffer (25 mM Tris-phosphate, 2 mM DTT, 2 mM diaminocyclohexane tetraacetic acid, 10% glycerol, 1% Triton X-100, 5 mM PMSF) for 10 min on ice. After centrifugation for 10 min at 13 000 r.p.m., the supernatant was collected and the protein concentration was determined using a spectrophotometer. Samples containing 40 mg of total protein were electrophoresed on 10% SDS-PAGE gels, and transferred to PVDF membranes. Anti-RORA antibody was obtained from Santa Cruz Biotechnology (Catalog no. sc-6062) and anti-actin antibody was from NeoMakers (Catalog no. 1295P405H). The secondary antibody was used to visualize the protein expression by an enhanced chemiluminescence detection kit (Amersham Biosciences, Buckinghamshire, UK; Catalog no. 25-0062-62) according to the manufacturer's instructions.
